At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Solange Peters, MD, PhD, from Lausanne University Hospital, Lausanne, Switzerland, discusses results from ASCEND-2 and ASCEND-3, both of which are single-arm, open-label, multicentre phase 2 clinical trials evaluating the efficacy and safety of ceritinib, a tyrosine kinase inhibitor, in patients with ALK-rearranged non-small cell lung cancer (NSCLC) and baseline brain metastases.
ASCEND-2 and ASCEND-3 trials: Ceritinib in ALK-rearranged NSCLC with brain metastases
25th May 2016
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?
Keep your finger on the pulseJoin Now
Elevating the Quality of Healthcare Globally